PPARGC1A and lip and oral cavity carcinoma: These data collectively highlight the potential benefit of combining PPARGC1A inhibitor (SR-18292) with current chemotherapy drugs such as cisplatin, shifting the balance toward excessive mitophagy-associated cell death in oral cancer cells in vitro.